BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POPULATION ANALYSIS OF NET CLINICAL BENEFIT

Schmitt C1, McCollum PL2, Creveling TL3, Oberdeck A4
1 Ei Lilly and Company, Windlesham, Surrey, UK, 2Ei Lilly and Company, Indianapolis, IN, USA, 3Duaxis Sarl, Europe GmbH, Munich, Germany

OBJECTIVES: TRITON-TIMI-38 showed reduction in atherothrombotic events with more intensive antiplatelet therapy with prasugrel versus clopidogrel, but with more bleeding. Patients without prior TIA/stroke, patients without any of 3 risk factors for bleeding (prior TIA/stroke, age ≥75 years, weight <60 kg) and patients with STEMI tended to have greater net clinical benefit. This analysis aims at determining which therapeutic strategy would optimize clinical outcomes in a real-life population with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) in Europe. METHODS: Published estimates from TRITON-TIMI-38 were used to predict clinical outcomes in a hypothetical population of 10,000 ACS-PCI patients. Strategies analysed were: clopidogrel for all (A), prasugrel for patients without prior TIA/stroke and clopidogrel for others (B), prasugrel for patients without prior TIA/stroke, age ≥75 years and weight ≥60 kg, clopidogrel for others (C), prasugrel for patients with STEMI, clopidogrel for others (D). Group sizes were derived from the APTOR observational study of 1,525 ACS-PCI patients recruited in Spain, UK and France in 2007. RESULTS: Of 10,000 ACS-PCI patients, 9,784 would have no prior TIA/stroke, 7,797 would have none of the bleeding risk factors above, 3,816 would have STEMI. Strategy A would result in 1,205 atherothrombotic events (composite endpoint of cardiovascular death, MI, stroke), 182 major haemorrhage events and 1,385 net clinical outcome events (composite endpoint of all cause death, MI, stroke or major haemorrhage). Alternative strategies would result in incremental events of, respectively, –24, –19, +19 and -196 (B), –211, +39 and –39 (C) and –211 and –92 (D). CONCLUSIONS: This model suggests prasugrel has a broad place in therapy based on net clinical benefit. Significantly restricted use would prevent disproportionately fewer atherothrombotic events relative to bleeding events. This model may be used to assist health care decision makers, along with our decision-analysis tools, in making recommendations for optimal use of clopidogrel and prasugrel.

OUTCOMES ASSESSMENT IN LOW & HIGH RISK P.T.C.A. PATIENTS

Singh S1, Mahatoor S2, Tiwari P1
1 National Institute of Pharmaceutical Education & Research, Mohali, Punjab, India, 2Fortis Malar��作al Hospita, Mohali, Punjab, India

OBJECTIVE: To attempt to correlate the costs and health outcomes of the patients who had undergone Percutaneous Transluminal Coronary Angioplasty (PTCA) with stenting. METHODS: This retrospective study analysed 258 patients who had undergone PTCA with stenting. Patients were divided into two groups: 1) those with low risk factors (0–2); 2) those with high risk factors (>2). Costs and risk factors were identified. Outcomes like average length of stay (LOS) [average intensive care unit (ICU), non-ICU, post-operative, total LOS], post surgical survival, post surgical complications, number of readmissions within 1 year for both the groups of patients with low and high risk factors in PTCA were assessed. RESULTS: The cost for PTCA (in lakhs ± standard error of mean (SEM)) was higher in the patients with high risk factors (3.23 ± 0.16 lakhs) as compared to the patients with low risk factors (2.75 ± 0.07 lakhs). The patients with high risk factors had a longer LOS (ICU, non-ICU, post-operative, total LOS), slightly lower survival rate, higher incidence of post surgical complications and higher readmission rate within 1 year as compared to the patients with low risk factors. A total of 72 (approx. 30%) patients who underwent PTCA with stenting were readmitted within 1 year. Reasons for readmissions within one year were determined. On readmission, PTCA with stenting were performed in 36% of patients, followed by coronary angiography (33%), medical management (28%), and coronary artery by-pass grafting (14%). CONCLUSIONS: High risk patients had a longer length of stay, higher incidence of post surgical complications, poorer survival and higher readmission rate. These results have provided an insight into the costs and outcomes associated with PTCA and will help patients as well as interventionists in decision making regarding allocation of resources for a specific groups or subgroup of patient population.

PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008: CZECH REPUBLIC BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

Covařík Z1, Nörlbach K1, Hronkova M1, Pogat M2, Sarrat M3, Schmitt C1
1 Bata regional Hospital, Zlín, Czech Republic, 2Ei Lilly and Company Ltd, Windlesham, Surrey, UK, 3Ei Lilly and Company Ltd, Vienna, Austria, 4Ei Lilly and Company Ltd, Hamburg, France

OBJECTIVES: This analysis aims to explore management of acute coronary syndromes (ACS) from acute event to hospital discharge in Czech Republic, and to measure Quality of Life (QoL) at discharge. METHODS: This 12-month international prospective, observational study recruited ACS patients undergoing percutaneous coronary intervention (PCI), April–November 2008, capturing practice patterns, resource use and QoL. RESULTS: A total of 507 eligible ACS-PCI patients were included: median age 61 (IQR 54–69), median weight 84 (IQR 75–95), 24% female, 23% Type 2 diabetes, and 16% prior myocardial infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UANSTEMI) 43% and ST-elevation MI (STEMI) 57%. Almost all patients (97%) were implanted with stents; 83% bare metal stents (BMS) only, 14% drug eluting stents (DES) only and 3% both. Time from ACS to PCI was 3 days or less for 40% of UANSTEMI patients. Antiplaeter loading oral medications used: aspirin 84% and clopidogrel 98% (no use of ticlopidine). Clopidogrel loading dose (LD) was administered in carcinetherapy lab-26%, previous hospital-22%, ambulance-19%, coronary care unit-19%, emergency room-6%, intensive care unit-3%, and other-5% and near PCI (previous 6 hours, during PCI, following 6 hours) in 9% of cases. Total clopidogrel LD was above 300 mg in 56% of cases and in hospital maintenance dose (MD) was 75 mg in 99%. At time of hospital discharge, 98% of patients were receiving clopidogrel (SD) dose 75 mg in all cases and QoL was good: median EQ-5D health state index at 1.00 (IQR 0.80–1.00). CONCLUSIONS: These real life data reflect treatment patterns among ACS patients managed by PCI in Czech Republic in 2008. Time from ACS to PCI is very low especially in patients with STEMI. During PCI, DES are implanted six times less often than BMS. The QoL of patients at discharge was high.

A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG FRENCH PATIENTS IN PRIMARY CARE

Laforest L1, Ambagaskar BM1, Souchet TP1, Sazonov V1, Van Garsee E2
1CHU Lyon, Bron Cedex, France, 2CHU Lyon, Bron Cedex, France

OBJECTIVES: In this cross-sectional study we attempted to identify the extent of prevalence of low high density lipoprotein cholesterol (HDL-C) and/or elevated triglycerides (TG) combined with low density lipoprotein cholesterol (LDL-C) among statin treated patients in French clinical practice. METHODS: We used BKL-THALES database we identified patients who were treated with a statin for at least six months and also had a complete lipid profile (LDL-C, HDL-C and TG) within the past six months. Patients were considered to be at high CV risk if they had a history of CV disease, diabetes or 10 year CHD risk ≥20%. National guidelines in France (AES/ASSP) were used to define lipid threshold levels. Based on these guidelines, HDL-C and TG threshold levels were ≥0.40 g/l and ≤1.5 g/l whereas, LDL-C threshold levels were ≥1.0 g/l depending on the number of risk factors and the level of CV risk. RESULTS: In a sample of 2344 patients treated with statins (93% as monotherapy), approximately 51% patients (n = 1292) experienced ≥1 lipid abnormalities. Among these, 55% had elevated LDL-C while approximately 25% had elevated HDL-C along with LDL-C and/or TG abnormality. Nearly half (n = 1281) of the sample were high CV risk patients with 71% (n = 854) experiencing ≥1 lipid abnormalities. Among the latter, prevalence of elevated LDL-C was 72%, whereas nearly one-third experienced low HDL-C and/or elevated TG combined with elevated LDL-C. CONCLUSIONS: In this cross-sectional study of French patients half of all patients (approximately 51%) had ≥1 lipid abnormalities (chiefly among high CV risk) with at least one lipid abnormalities experienced elevated LDL-C. In addition, up to one-third of high CV risk patients experienced low HDL-C and/or elevated TG disorders along with elevated LDL-C and could potentially benefit from other lipid-modifying therapies besides statins.